What type of study is this?

Differential Responses to Targeted Therapies in Non-Small Cell Lung Cancer: A Comparative Analysis of Outcomes in Patients with Single EGFR Mutation and Concurrent Gene Alterations

View Full Paper

Ask AI

Bookmark

Concurrent gene alterations in EGFR-mutant patients reduce effectiveness of EGFR-TKIs, affecting outcomes.
Among 109 patients studied, the overall response rate was 67% with significant differences in PFS for single vs concurrent mutations.
This retrospective cohort study utilized next-generation sequencing data from January 2019 to June 2023.
The analysis indicates that patients with certain concurrent mutations face worse predictive outcomes, emphasizing the need for tailored therapies.

No takes yet. Share an insight, caveat, or question.

Retrospective cohort study shows varied treatment responses to EGFR-TKIs in patients with EGFR mutation and concurrent gene alterations.

Le et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark